24 July 2015 | News | By BioSpectrum Bureau
True Diagnostics' thyroid kit receives CFDA nod
With nearly 98 million Chinese suffering from thyroid disease, the new technology will aid in immediate patient treatment and reducing disease burden
Singapore: True Diagnostics, a leading global point-of-care company, announced today that it has received the China FDA nod for its JIANJIE(TM) TSH Test and BOCHI(TM) Reader. The JIANJIE TSH test kit and BOCHI reader uses True's proprietary TrueDX Platform that helps in easy and accurate diagnosis of thyroid ailments.
With nearly 98 million Chinese suffering from thyroid disease, the new technology will aid in administering remote-care thus helping in immediate patient treatment and reducing disease burden. The TrueDX Platform is capable of delivering increased stability and linearity over competing diagnostic platforms designed specifically for the laboratory.
Mr Jerry Lee, President and CEO of True, stated, "This recent regulatory clearance brings us one step closer to providing medical professionals and patients access to accurate, faster and more cost-effective care."
He added that through strategic partnerships, True Diagnostics has designed programs to help communities in need of thyroid disease monitoring. "People of China require better access to affordable and precise diagnostic options for early identification and disease management," observed Mr Lee